CN109069500A - 一种用于治疗胃癌的喹啉衍生物 - Google Patents

一种用于治疗胃癌的喹啉衍生物 Download PDF

Info

Publication number
CN109069500A
CN109069500A CN201780022398.0A CN201780022398A CN109069500A CN 109069500 A CN109069500 A CN 109069500A CN 201780022398 A CN201780022398 A CN 201780022398A CN 109069500 A CN109069500 A CN 109069500A
Authority
CN
China
Prior art keywords
compound
milligrams
gastric cancer
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780022398.0A
Other languages
English (en)
Other versions
CN109069500B (zh
Inventor
陈杰
韩溪
江海
王训强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN202211146855.6A priority Critical patent/CN115487187B/zh
Priority to CN202211146699.3A priority patent/CN115624550B/zh
Publication of CN109069500A publication Critical patent/CN109069500A/zh
Application granted granted Critical
Publication of CN109069500B publication Critical patent/CN109069500B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本申请提供了一种用于治疗胃癌的喹啉衍生物。本申请所提供的1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺或其药学上可接受的盐、水合物或前药能够有效治疗胃癌，能够稳定或者缓解胃癌患者病情。

Description

PCT国内申请，说明书已公开。

Claims (34)

  1. PCT国内申请，权利要求书已公开。
CN201780022398.0A 2016-04-15 2017-04-14 一种用于治疗胃癌的喹啉衍生物 Active CN109069500B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202211146855.6A CN115487187B (zh) 2016-04-15 2017-04-14 一种用于治疗胃癌的喹啉衍生物
CN202211146699.3A CN115624550B (zh) 2016-04-15 2017-04-14 一种用于治疗胃癌的喹啉衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016102381577 2016-04-15
CN201610238157.7A CN107296811B (zh) 2016-04-15 2016-04-15 一种用于治疗胃癌的喹啉衍生物
PCT/CN2017/080563 WO2017177962A1 (zh) 2016-04-15 2017-04-14 一种用于治疗胃癌的喹啉衍生物

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202211146699.3A Division CN115624550B (zh) 2016-04-15 2017-04-14 一种用于治疗胃癌的喹啉衍生物
CN202211146855.6A Division CN115487187B (zh) 2016-04-15 2017-04-14 一种用于治疗胃癌的喹啉衍生物

Publications (2)

Publication Number Publication Date
CN109069500A true CN109069500A (zh) 2018-12-21
CN109069500B CN109069500B (zh) 2022-11-04

Family

ID=60042370

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201610238157.7A Active CN107296811B (zh) 2016-04-15 2016-04-15 一种用于治疗胃癌的喹啉衍生物
CN202211146699.3A Active CN115624550B (zh) 2016-04-15 2017-04-14 一种用于治疗胃癌的喹啉衍生物
CN201780022398.0A Active CN109069500B (zh) 2016-04-15 2017-04-14 一种用于治疗胃癌的喹啉衍生物
CN202211146855.6A Active CN115487187B (zh) 2016-04-15 2017-04-14 一种用于治疗胃癌的喹啉衍生物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201610238157.7A Active CN107296811B (zh) 2016-04-15 2016-04-15 一种用于治疗胃癌的喹啉衍生物
CN202211146699.3A Active CN115624550B (zh) 2016-04-15 2017-04-14 一种用于治疗胃癌的喹啉衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211146855.6A Active CN115487187B (zh) 2016-04-15 2017-04-14 一种用于治疗胃癌的喹啉衍生物

Country Status (5)

Country Link
US (1) US10736887B2 (zh)
EP (1) EP3443962B1 (zh)
JP (1) JP2019513789A (zh)
CN (4) CN107296811B (zh)
WO (1) WO2017177962A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112043832A (zh) * 2019-06-06 2020-12-08 正大天晴药业集团股份有限公司 用于联合治疗胃癌的喹啉类化合物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3231797B1 (en) 2014-12-09 2020-02-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative against non-small cell lung cancer
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
ES2782113T3 (es) 2015-07-11 2020-09-10 Advenchen Pharmaceuticals Llc Compuestos de quinolina fusionados como inhibidores de PI3K/mTor
CN115057815A (zh) 2018-03-02 2022-09-16 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途
JP7270633B2 (ja) * 2018-03-14 2023-05-10 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 上咽頭がん治療用キノリン誘導体
EP3854396A4 (en) * 2018-09-18 2022-06-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative used for treating small cell lung cancer
AU2020273687A1 (en) * 2019-05-10 2022-01-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative used for soft tissue sarcoma combination therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103483319A (zh) * 2007-03-14 2014-01-01 南京爱德程医药科技有限公司 作为血管生成抑制剂的螺取代化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US9370508B2 (en) 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
WO2009155527A2 (en) 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
IT1393351B1 (it) 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
CN103664892B (zh) 2010-08-01 2015-09-02 正大天晴药业集团股份有限公司 喹啉衍生物的结晶
CN102225067B (zh) * 2011-04-29 2012-10-03 济南环肽医药科技有限公司 一种治疗胃癌的药物组合物
AU2012339342B2 (en) 2011-11-14 2016-02-11 Centaurus Biopharma Co., Ltd. Kinase modulating compounds, compositions containing the same and use thereof
CN104936946A (zh) 2013-01-18 2015-09-23 爱德程制药有限公司 制备抗肿瘤剂6-(7-((1-氨基环丙基)甲氧基)-6-甲氧基喹啉-4-基氧基)-n-甲基-1-萘甲酰胺的方法及其结晶
CN104513229A (zh) 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN105213394B (zh) * 2014-06-06 2019-04-09 正大天晴药业集团股份有限公司 具有抗肿瘤活性的喹啉衍生物
CN105311030B (zh) 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN105311029A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
AU2015290007B2 (en) 2014-07-14 2019-11-21 Advenchen Pharmaceuticals, Nanjing Ltd. Fused quinoline compunds as pi3k, mTor inhibitors
EP3231797B1 (en) 2014-12-09 2020-02-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative against non-small cell lung cancer
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
ES2782113T3 (es) 2015-07-11 2020-09-10 Advenchen Pharmaceuticals Llc Compuestos de quinolina fusionados como inhibidores de PI3K/mTor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103483319A (zh) * 2007-03-14 2014-01-01 南京爱德程医药科技有限公司 作为血管生成抑制剂的螺取代化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112043832A (zh) * 2019-06-06 2020-12-08 正大天晴药业集团股份有限公司 用于联合治疗胃癌的喹啉类化合物

Also Published As

Publication number Publication date
US10736887B2 (en) 2020-08-11
EP3443962A1 (en) 2019-02-20
EP3443962B1 (en) 2023-03-29
EP3443962A4 (en) 2019-12-25
WO2017177962A1 (zh) 2017-10-19
CN107296811B (zh) 2022-12-30
CN115487187A (zh) 2022-12-20
CN109069500B (zh) 2022-11-04
CN107296811A (zh) 2017-10-27
CN115624550A (zh) 2023-01-20
US20190125739A1 (en) 2019-05-02
CN115624550B (zh) 2024-08-06
CN115487187B (zh) 2024-08-06
JP2019513789A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
CN109069500A (zh) 一种用于治疗胃癌的喹啉衍生物
EP3231797B1 (en) Quinoline derivative against non-small cell lung cancer
CN106413712B (zh) 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物
JP6511117B2 (ja) アジュバント癌治療の方法
CN108135901A (zh) 胆管癌的治疗
CN108601778A (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
WO2018214925A1 (zh) 用于治疗结直肠癌的喹啉衍生物
CN115590852A (zh) 治疗非小细胞肺癌的喹啉衍生物
CN103054871A (zh) 抗肿瘤效果增强剂、抗肿瘤剂和癌治疗方法
CN112584834B (zh) 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物
CN111757736B (zh) 治疗鼻咽癌的喹啉衍生物
CN113893256A (zh) 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用
CN106999485B (zh) 抗肺鳞癌的喹啉衍生物
CN114761010B (zh) 喹唑啉衍生物或其盐的联用药物组合物及其用途
CN111939165B (zh) 非天然人参皂苷3β-O-Glc-DM在制备预防或治疗胶质母细胞瘤药物中的应用
CN112105361A (zh) 用于治疗非小细胞肺癌的喹啉衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261169

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369

Applicant before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

GR01 Patent grant
GR01 Patent grant